Drug Slashes Cardiovascular Events for Diabetes Patients

Data on 1,791 type 2 diabetes patients who were on metformin treatment showed that those who took bromocriptine-QR had a 53% decline in cardiovascular events compared with the placebo arm. The findings were presented at the American Heart Association meeting. ADA Scientific Sessions 2013